EXEL
CABOMETYX still gets the first billing
Exelixis is basically telling investors: the current cash engine is still humming, but don’t get too comfortable. The company said it plans to keep expanding CABOMETYX while preparing for a possible zanzalintinib launch in colorectal cancer later this year.
That matters because CABOMETYX has been the company’s reliable workhorse. If you own EXEL, you’re watching for the classic biotech problem: how long can one franchise carry the team before the next one has to step up?
The zanza question
Zanzalintinib, or “zanza” if you’re into biotech nicknames that sound like a Marvel side character, is the next catalyst investors are eyeing. A launch in colorectal cancer could open a new growth lane, but launches are never as simple as flipping a switch.
What investors care about now:
- whether CABOMETYX can keep growing without losing steam
- whether zanza gets to market on time later this year
- whether the new asset can become more than just a shiny pipeline promise
Why the stock cares
This isn’t just pipeline theater. Exelixis is trying to prove it can graduate from a one-hit wonder into a multi-franchise story. If zanza lands well, the market may start treating EXEL less like a mature oncology name and more like a company with another leg to stand on.
Big picture: the company still has to execute, but at least it’s giving investors a reason to look past the old album and wait for the encore.